Feature | August 20, 2012

Baylor Heart Hospital First in the World to Merge Two High-Tech Systems for AFib Therapy

Merging to result in reduced procedure time and higher likelihood of favorable outcome

August 20, 2012 — The Baylor Heart Hospital in Plano, Texas, recently became the first hospital in the world to merge two highly advanced technologies for atrial fibrillation (AF) therapy.

The procedure combined the use of multi-electrode mapping (MEM) software with the Epoch platform, making the full-service cardiovascular hospital the first in the world to do so. Introduced by Biosense Webster, the software allows the physician maneuvering a MEM-enabled catheter to acquire multiple mapping points simultaneously with a higher level of detail. The Epoch platform is an advanced computer-controlled technology that allows physicians to navigate within the patient's heart with robotic precision.

Merging these two technologies means higher levels of efficiencies in mapping and correcting the patient’s cardiac arrhythmias. J. Brian DeVille, M.D., FACC, FHRS, medical director of electrophysiology and an electrophysiologist on the medical staff of the Baylor Heart Hospital, said this first-in-the-world procedure is an important step to further advancing patient care in the arena of cardiac electrophysiology.

“The integration of these two technologies confirms the Heart Hospital Baylor Plano’s commitment to excellence in patient care and providing advanced treatment to our patients,” DeVille said. “Our goal is always to seek ways to further minimize risk to the patient, which then increases the probability of favorable outcomes.”

Mark Valentine, the hospital’s president, added, “The Heart Hospital is fully committed to improving patient outcomes and that involves implementing advanced technologies that will help us fulfill that goal. We consistently strive to be on the forefront when it comes to innovation because we know that ultimately that is what will serve our patients’ interests in positive ways and help us continue to provide safe, quality, compassionate care.”

For more information: www.thehearthospitalbaylor.com

Related Content

Sponsored Content | Videos | Leads Implantable Devices| May 25, 2017
Bruce Wilkoff, M.D., director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic, discusses advancemen
Biotronik Home Monitoring implanted EP device remote wireless monitoring system
News | May 24, 2017
May 23, 2017 – Results now published in the European Heart Journal show Biotronik Home Monitoring reduces th
Sponsored Content | Videos | Pacemakers| May 23, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
Sponsored Content | Videos | Cardiac Resynchronization Therapy Devices (CRT)| May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation Endocar
Sponsored Content | Videos | Atrial Fibrillation| May 17, 2017
Hugh Calkins, M.D., FACC, FAHA, FHRS, director of cardiac arrhythmia services and professor of medicine at Johns Hopk
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Sponsored Content | Videos | EP Lab| May 17, 2017
This video, provided by Spectranetics, demonstrates how to deploy the Bridge Occlusion Balloon used to seal accidenta
Spectranetics Bridge Occlusion Balloon in the SVC

An illustration of how the Bridge balloon can seal the SVC after an accidental tear from lead extration.

Feature | EP Lab| May 17, 2017 | Dave Fornell
May 17, 2017 — A new intravenous occlusion balloon designed to seal any accidental tears in the superior vena cava (S
Medtronic Reveal Linq implantable cardiac monitor

The Medtronic Reveal Linq implantable cardiac monitor is the smallest implantable monitor on the market. It is used as a long-term Holter monitor for 24-hour a day, 365-day a year patient monitoring. The device uses wireless connectivity to download the patient data with a patient bedside base unit to send the information over the internet so it is accessible by physicians.

Feature | Atrial Fibrillation| May 16, 2017
May 16, 2017 - The study using small, subcutaneous implantable cardiac monitors for long-term, 24-hour a day monitori
Overlay Init